← Back to Search

Alkylating agents

Cyclophosphamide for Pancreatic Cancer

Phase 2
Waitlist Available
Led By Lei Zheng, MD, PhD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Locally advanced pancreatic adenocarcinoma
Patients must have received mFOLFIRINOX or Gemcitabine/ Abraxane based chemotherapy for 4 cycles with last dose of therapy between 2-5 weeks of study enrollment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 62 months
Awards & highlights

Study Summary

This trial will be testing a combination of drugs and radiation to treat pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~62 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 62 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Distant Metastasis Free Survival (DMFS)
Secondary outcome measures
Number of Participants Experiencing a Grade 3 or Above Treatment Related Toxicities

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cyclophosphamide, Pembrolizumab, GVAX Pancreas Vaccine, SBRTExperimental Treatment4 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
1995
Completed Phase 3
~3780
GVAX Pancreatic Cancer Vaccine
2016
Completed Phase 2
~60
Pembrolizumab
2017
Completed Phase 2
~1950
SBRT
2014
Completed Phase 2
~1060

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,862 Previous Clinical Trials
5,049,651 Total Patients Enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
554 Previous Clinical Trials
32,853 Total Patients Enrolled
Lei Zheng, MD, PhDPrincipal InvestigatorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2 Previous Clinical Trials
85 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Pembrolizumab is most often used for what type of patient?

"Pembrolizumab can be used to fight against three types of cancer: malignant melanoma of the skin, recurrent cervical cancer, and leukemia."

Answered by AI

What is the maximum level of risk that patients face when taking Pembrolizumab?

"While there is some supportive data, pembrolizumab's safety falls in the middle of the spectrum with a score of 2."

Answered by AI

Are there any spots left for people who want to enroll in this trial?

"From what is displayed on clinicaltrials.gov, it appears that this trial is no longer recruiting patients. Although this study is not currently looking for any new candidates, there are 2535 other trials that are."

Answered by AI

Are there other similar drugs to Pembrolizumab that have been studied?

"Right now, 1813 clinical trials involving Pembrolizumab are active with 278 in Phase 3. Out of these studies, several are based in Philadelphia, Pennsylvania. But, in total, there are 63006 locations running trials for Pembrolizumab."

Answered by AI

How many people have been allowed to participate in this research project?

"Although this specific trial is not recruiting at the moment, it was updated recently on June 3rd, 2022. There are currently 722 other trials actively recruiting patients with cancer of the pancreas and 1813 trials for Pembrolizumab."

Answered by AI
~7 spots leftby Mar 2025